bioRxivCancer BiologyPreprint
Tumor irradiation combined with vascular-targeted photodynamic therapy enhances anti-tumor effects in preclinical prostate cancer.
H. T. Sjoberg, Y. J. Philippou, A. L. Magnussen, I. D. Tullis, E. Bridges, A. Chatrian, J. Loefebvre, K. H. Tam, E. A. Murphy, J. Rittscher, D. Preise, L. Agemy, T. Yechezkel, S. C. Smart, P. Kinchesh, S. Gilchrist, D. P. Allen, D. A. Scheiblin, S. J. Lockett, D. A. Wink, A. D. Lamb, I. G. Mills, A. Harris, R. J. Muschel, B. Vojnovic, , R. J. Bryant
Abstract
RationaleThere is an important clinical need to improve the treatment of high risk localized and locally advanced prostate cancer (PCa), and to reduce the side effects of these treatments. We hypothesized that multi-modality therapy combining radiotherapy and vascular-targeted photodynamic therapy (VTP) could PCa tumour control compared against monotherapy with each of these treatments alone. This could provide proof-of-concept to take to the clinic. VTP is a focal therapy for localized PCa, which rapidly destroys targeted tumors through vascular disruption. Tumor vasculature is characterized by vessel immaturity, increased permeability, aberrant branching and inefficient flow. Fractionated radiotherapy (FRT) alters the tumor microenvironment and promotes transient vascular normalization. ObjectiveWe investigated whether sequential delivery of FRT followed by VTP 7 days later improves PCa tumor control compared to monotherapy with FRT or VTP alone. FindingsFRT induced vascular normalization changes in PCa flank tumor allografts, improving vascular function as demonstrated using dynamic contrast enhanced magnetic resonance imaging. FRT followed by VTP significantly delayed tumor growth in flank PCa allograft pre-clinical models, compared with monotherapy with FRT or VTP alone, and improved overall survival. ConclusionTaken together, these results suggest that combining FRT and VTP could become a promising multimodal clinical strategy in PCa therapy. This provides proof-of-concept for this multi-modality therapy approach to take forward to early phase clinical trials.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Focal radiotherapy improves CAR T cell therapy targeting prostate cancer
Cari A. Young, Jiangyue Liu, … Saul J. Priceman·bioRxiv·Jun 24, 2026
- Comparative effects of proton and photon irradiation on the molecular and cellular profiles of triple-negative breast cancer: the crucial impact of VEGFC on tumor microenvironment remodeling
Saharnaz Sarlak, Delphine Marotte, … Gilles Pagès·bioRxiv·Aug 19, 2024
- Targeted Drug Delivery by Radiation-Induced Tumor Vascular Modulation
Sijumon Kunjachan, Shady Kotb, … Ross Berbeco·bioRxiv·Feb 20, 2018
- Radioligand therapy in combination with CAR T cells overcomes the heterogeneous immunosuppressive prostate tumor microenvironment
Jiangyue Liu, Iveta Fajnorovà, … Saul J. Priceman·bioRxiv·Jul 3, 2026
- Modeling of chemo-radiotherapy targeting growing vascular tumors: a continuum-level approach
Ioannis Lampropoulos, Marina Koutsi, Michail E. Kavousanakis·PLoS ONEPeer-reviewed·Jan 15, 2025
- Radiopharmaceutical therapy for metastatic prostate cancer: Insights from mechanistic modeling and in silico trials
Matteo Italia, Silvia Bordel-Vozmediano, … Víctor M. Pérez‐García·bioRxiv·Dec 19, 2025